Recent 8-K filings for INDP
Highest-materiality recent filing
Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes
- Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.
- Authorized common stock increased from 200M to 1B shares; reverse stock split authorized at ratio 1:2 to 1:199.
-
Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left
Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).
-
Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns
Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.
-
Indaptus Therapeutics change of control: David Lazar sells $11.2M stake; new CEO Junyi Dai appointed
David Lazar sold 700K Series AAA and 196.8K Series AA Preferred shares to five purchasers for $11.2M.
-
Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes
Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.
-
Indaptus cuts co-CEO and CSO salaries to $60K/year; director rescinds resignation
Co-CEO Jeffrey A. Meckler and CSO Michael J. Newman salaries reduced to $60,000 per annum effective Jan 15, 2026.
-
Three Indaptus Therapeutics directors resign pending stockholder vote on Lazar nominees
Directors Michael Newman, Mark Gilbert, Anthony Maddaluna resigned effective upon approval of David Lazar's nominees at next stockholder meeting.
-
Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO
David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.
-
Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.
-
Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M
Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.
-
Indaptus reports Q2 net loss $9.09/sh; first patient dosed in Decoy20 combo trial with tislelizumab
Q2 2025 R&D expenses $2.2M (up $0.5M YoY); G&A $2.3M (down $0.1M YoY); net loss per share $9.09 vs. $13.16.
-
Raised gross proceeds of approximately $5.7 million in private placement of convertible notes and warrants, closed June 12 and June 30, 2025.
-
Indaptus raises additional $3.4M via convertible notes and warrants, total $5.7M
Second closing of private placement adds $3.4M in convertible notes; aggregate gross proceeds now $5.7M.
-
Indaptus Therapeutics implements 1-for-28 reverse stock split effective June 26, 2025
Reverse stock split at ratio of 1-for-28 effective after market close on June 26, 2025.
-
Indaptus raises $2.3M via convertible notes and warrants; up to $5M total
$2.3M aggregate principal of 6% convertible promissory notes; mature July 28, 2026.
-
Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.
-
Indaptus reports Q4 loss per share $1.61; cash $5.8M; Decoy20 trial enrolls >20 patients
Cash and equivalents $5.8M as of Dec 31, 2024; Jan 2025 private placement raised net $2.0M.
-
Indaptus enters $20M standby equity line with Yorkville; issues 305,960 commitment shares
Up to $20M equity purchase agreement with YA II PN (Yorkville) over 36 months.
-
Indaptus receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
Received Nasdaq notice on Jan 31, 2025 for non-compliance with minimum bid price of $1.00 per share.
-
Indaptus raises $2.25M in private placement of stock and warrants at $1.065/unit
Gross proceeds of $2.25M from sale of 2,109,383 shares and warrants to purchase 2,109,383 shares (combined price $1.065/unit).
-
Indaptus Therapeutics prices $2.135M offering of stock and warrants at $1.175/unit
Sold 1,817,017 shares of common stock and warrants to buy 1,817,017 shares at $1.175 per unit.
-
Indaptus Q3 2024: EPS -$0.32, cash $7.4M; Decoy20 Phase 1 expands with BeiGene deal
Q3 2024 net loss $0.32 per share (vs $0.47 loss in Q3 2023); nine-month loss $1.23 per share (vs $1.36 loss).
-
Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion
Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.
-
Indaptus Therapeutics reports Q1 2024 results; R&D expense down 15% YoY
R&D expenses $1.6M, down $0.3M or 15% vs Q1 2023; G&A expenses $2.4M, down 9%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.60 · Most common event other_material